Osprey Medical Inc
(ASX:OSP) says its received approval from the US Food and Drug Administration to expand on the marketing claims of its DyeVert system.
The system protects patients from the harmful effects of X-ray dye and the latest tests show the DyeVert system delivers around 45 per cent of dye savings without compromising image quality.
The commercialisation process has just begun and of the 24 hospitals that have evaluated the system 11 have already placed orders with 13 seeking approval to purchase the system.
The FDA clearance of claims will allow stronger marketing of the products.
Osprey Medical reported a net loss of $8.2 million for the 2015 financial year.
